Executive Summary Written by Jonathan Wright, British Clinical Pharmacist Last reviewed: February 2026 Glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have transformed the treatment of obesity and type 2 diabetes
And how fast
In the Phase 2 trial protocol, participants reached the 12mg maximum dose at week 20 after five escalation steps (1mg, 2mg, 4mg, 8mg, 12mg), each held for four weeks
We look forward to additional cardiovascular outcome trials in patients with obesity. The trial was sponsored by Novo Nordisk, the company that markets semaglutide
Beyond Insulin: Using Ozempic and Other Off-Label Drugs for Type 1 Diabetes What Are The Medications For Type 1 Diabetes
"I know lots of stories of social media pushing weight loss ads to small children watching YouTube [or] amplifying content to people who are already struggling with disordered eating." Calls for 'stronger safeguards' and 'greater accountability' for GLP-1 access At its peak in June 2024, Ozempic-maker Novo Nordisk was worth as much as $US615 billion ($940.40 billion)
